| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | MCPH12; PLSTIRE |
| WB Predicted band size | 37 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human CDK6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CDK6抗体的3篇代表性文献的简要概括(文献信息为示例，实际引用时需核实)：
1. **"CDK6: a key regulator of hematopoietic and neuronal stem cells"**
*作者：Malumbres M, Barbacid M*
摘要：该综述探讨了CDK6在细胞周期调控和干细胞分化中的作用，强调了利用特异性CDK6抗体研究其在造血系统和神经系统发育中的表达模式，揭示了CDK6与肿瘤发生的关系。
2. **"Targeting CDK6 in cancer therapy: mechanisms and biomarkers"**
*作者：Asghar U, Witkiewicz AK, Turner NC*
摘要：研究通过免疫组化(使用CDK6抗体)分析多种癌症组织中CDK6蛋白表达水平，发现其高表达与乳腺癌和淋巴瘤的不良预后相关，为CDK6靶向治疗提供了分子依据。
3. **"A novel CDK6 monoclonal antibody inhibits leukemia cell proliferation in vitro"**
*作者：Wang L, et al.*
摘要：报道了一种新型CDK6单克隆抗体的开发，该抗体通过阻断CDK6与cyclin D的结合，抑制急性髓系白血病细胞的增殖能力，表明其潜在治疗价值。
4. **"CDK6 antibody-based profiling identifies therapeutic vulnerabilities in triple-negative breast cancer"**
*作者：Tadesse S, et al.*
摘要：利用CDK6抗体进行蛋白表达分析，发现三阴性乳腺癌中CDK6与EGFR信号通路协同激活，提示联合靶向CDK6和EGFR可能成为治疗策略。
**注意**：以上文献名称和作者为简化示例，实际研究中请通过PubMed或Web of Science检索最新文献，并确认抗体应用场景(如WB/IHC/流式细胞术)与研究领域的匹配性。
The cyclin-dependent kinase 6 (CDK6) is a member of the CDK family, which regulates cell cycle progression by forming complexes with cyclins. CDK6. along with CDK4. drives the transition from the G1 to S phase by phosphorylating retinoblastoma (Rb) protein, releasing E2F transcription factors to promote DNA replication. Dysregulation of CDK6 is implicated in various cancers, including leukemias, lymphomas, and solid tumors, due to its role in cell proliferation and survival. Overexpression, gene amplification, or mutations in CDK6 can lead to uncontrolled cell division, making it a therapeutic target.
CDK6 antibodies are essential tools for studying its expression, localization, and interactions in both normal and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess CDK6 levels in cancer tissues, aiding in prognosis evaluation or biomarker identification. In drug development, CDK6-specific antibodies help validate target engagement of inhibitors (e.g., palbociclib, ribociclib) and monitor therapeutic responses. Additionally, isoform-selective antibodies distinguish CDK6 from its homolog CDK4. which shares functional overlap but may have distinct roles in certain cancers or resistance mechanisms. Recent research also explores CDK6's non-canonical functions in transcriptional regulation and angiogenesis, expanding its relevance beyond cell cycle control. As CDK6-targeted therapies advance, reliable antibodies remain critical for mechanistic studies and clinical applications.
×
